The role of b-type natriuretic peptide in heart failure management

Phillip J. Newton; Vasiliki Betihavas; Peter Macdonald

doi:10.1016/j.aucc.2009.06.001

The role of b-type natriuretic peptide in heart failure management

Phillip J. Newton, Vasiliki Betihavas, Peter Macdonald

Western Sydney University

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Heart failure is a complex clinical syndrome that manifests itself with signs and symptoms which are neither sensitive nor specific for the diagnosis of heart failure. Natriuretic peptides and in particular b-type natriuretic peptide (and nt-proBNP) are widely used in clinical practice around the world as a maker of heart failure. BNP is primarily released from the left ventricle in response to pressure and volume overload. The strongest evidence for the use of BNP is to rule in or rule out heart failure as cause of breathlessness in people who present to the emergency room. There is enthusiasm for use of BNP as a marker of heart failure severity as well as a predictor of outcomes in people with heart failure and trials are ongoing. Nesiritide, a recombinant form of BNP is currently being tested as a possible treatment in people with acutely decompensated heart failure.

Original language	English
Pages (from-to)	117-123
Number of pages	7
Journal	Australian Critical Care
Volume	22
Issue number	3
DOIs	https://doi.org/10.1016/j.aucc.2009.06.001
Publication status	Published - 2009

Keywords

biochemical markers
heart failure
natriuretic peptides

Access to Document

10.1016/j.aucc.2009.06.001

Cite this

@article{623f04c0653e44719f8776967b6f3a21,

title = "The role of b-type natriuretic peptide in heart failure management",

abstract = "Heart failure is a complex clinical syndrome that manifests itself with signs and symptoms which are neither sensitive nor specific for the diagnosis of heart failure. Natriuretic peptides and in particular b-type natriuretic peptide (and nt-proBNP) are widely used in clinical practice around the world as a maker of heart failure. BNP is primarily released from the left ventricle in response to pressure and volume overload. The strongest evidence for the use of BNP is to rule in or rule out heart failure as cause of breathlessness in people who present to the emergency room. There is enthusiasm for use of BNP as a marker of heart failure severity as well as a predictor of outcomes in people with heart failure and trials are ongoing. Nesiritide, a recombinant form of BNP is currently being tested as a possible treatment in people with acutely decompensated heart failure.",

keywords = "biochemical markers, heart failure, natriuretic peptides",

author = "Newton, {Phillip J.} and Vasiliki Betihavas and Peter Macdonald",

year = "2009",

doi = "10.1016/j.aucc.2009.06.001",

language = "English",

volume = "22",

pages = "117--123",

journal = "Australian Critical Care",

issn = "1036-7314",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - The role of b-type natriuretic peptide in heart failure management

AU - Newton, Phillip J.

AU - Betihavas, Vasiliki

AU - Macdonald, Peter

PY - 2009

Y1 - 2009

N2 - Heart failure is a complex clinical syndrome that manifests itself with signs and symptoms which are neither sensitive nor specific for the diagnosis of heart failure. Natriuretic peptides and in particular b-type natriuretic peptide (and nt-proBNP) are widely used in clinical practice around the world as a maker of heart failure. BNP is primarily released from the left ventricle in response to pressure and volume overload. The strongest evidence for the use of BNP is to rule in or rule out heart failure as cause of breathlessness in people who present to the emergency room. There is enthusiasm for use of BNP as a marker of heart failure severity as well as a predictor of outcomes in people with heart failure and trials are ongoing. Nesiritide, a recombinant form of BNP is currently being tested as a possible treatment in people with acutely decompensated heart failure.

AB - Heart failure is a complex clinical syndrome that manifests itself with signs and symptoms which are neither sensitive nor specific for the diagnosis of heart failure. Natriuretic peptides and in particular b-type natriuretic peptide (and nt-proBNP) are widely used in clinical practice around the world as a maker of heart failure. BNP is primarily released from the left ventricle in response to pressure and volume overload. The strongest evidence for the use of BNP is to rule in or rule out heart failure as cause of breathlessness in people who present to the emergency room. There is enthusiasm for use of BNP as a marker of heart failure severity as well as a predictor of outcomes in people with heart failure and trials are ongoing. Nesiritide, a recombinant form of BNP is currently being tested as a possible treatment in people with acutely decompensated heart failure.

KW - biochemical markers

KW - heart failure

KW - natriuretic peptides

UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:42942

U2 - 10.1016/j.aucc.2009.06.001

DO - 10.1016/j.aucc.2009.06.001

M3 - Article

SN - 1036-7314

VL - 22

SP - 117

EP - 123

JO - Australian Critical Care

JF - Australian Critical Care

IS - 3

ER -

The role of b-type natriuretic peptide in heart failure management

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this